$4.05 0.1 2.3%
Last Trade - 22/01/21
| Market Cap | ÂŁ251.3m |
| Enterprise Value | ÂŁ164.9m |
| Revenue | ÂŁ4.49m |
| Position in Universe | 3766th / 6630 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 15.0 | 23.3 | 1.49 | 10.7 | 5.95 | 6.01 | 6.54 | 9.51 | -16.7% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | January 1, 2018 |
| Public Since | November 13, 2010 |
| No. of Shareholders: | 102 |
| No. of Employees: | 80 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 84,909,258 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 701 Veterans Circle, WARMINSTER, 18974, United States |
| Web | http://www.arbutusbio.com/ |
| Phone | +1 267 4690914 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 22/01/21, shares in Arbutus Biopharma are trading at $4.05, giving the company a market capitalisation of ÂŁ251.3m. This share price information is delayed by 15 minutes.
Shares in Arbutus Biopharma are currently trading at $4.05 and the price has moved by 29.81% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arbutus Biopharma price has moved by 11.02% over the past year.
Of the analysts with advisory recommendations for Arbutus Biopharma, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arbutus Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Arbutus Biopharma is scheduled to issue upcoming financial results on the following dates:
Arbutus Biopharma does not currently pay a dividend.
Arbutus Biopharma does not currently pay a dividend.
Arbutus Biopharma does not currently pay a dividend.
To buy shares in Arbutus Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Arbutus Biopharma are currently trading at $4.05, giving the company a market capitalisation of ÂŁ251.3m.
Here are the trading details for Arbutus Biopharma:
Based on an overall assessment of its quality, value and momentum, Arbutus Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Arbutus Biopharma are currently priced at $4.05. At that level they are trading at 72.84% discount to the analyst consensus target price of 0.00.
Analysts covering Arbutus Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -0.98 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arbutus Biopharma. Over the past six months, the relative strength of its shares against the market has been -31.35%. At the current price of $4.05, shares in Arbutus Biopharma are trading at 41.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Arbutus Biopharma.
Arbutus Biopharma's management team is headed by:
Here are the top five shareholders of Arbutus Biopharma based on the size of their shareholding:
